All News

The @ACRheum RA outcome measures toolkit has all the relevant tools for measuring outcomes in rheumatoid arthritis (and exactly how to do it). https://t.co/GZ7tZ6fNMK Great for all US rheumatologists, but also very handy for all of us globally #ACR24 16S30 @JYazdany @RheumNow https://t.co/MSHA353MKR

Links:

David Liew drdavidliew ( View Tweet)
The @ACRheum RA outcome measures toolkit has all the relevant tools for measuring outcomes in rheumatoid arthritis (and exactly how to do it). https://t.co/GZ7tZ6fNMK Great for all US rheumatologists, but also very handy for all of us globally #ACR24 16S30 @JYazdany @RheumNow https://t.co/MSHA353MKR

Links:

David Liew drdavidliew ( View Tweet)
Meeting audience conference

ACR 2024 - Day 1 Report

d Jack Cush, MD

ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings.  The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.

Read Article
pregnant, pregnancy, mother, fertility

Is Pregnancy Truly the Solution for RA?

d Eric Dein, MD

Pregnancy is perhaps the oldest treatment in rheumatoid arthritis (RA) and has been associated with a natural improvement in disease control in 50-75% of patients. Others, however, are not as successful with unchanged disease activity or worsening of their autoimmune disease.

Read Article
RheumNow Day 1 Recap: ACR Convergence 2024 Highlights https://t.co/xjCMpzXhTE

Links:

Dr. John Cush RheumNow ( View Tweet)

Race of b/tsDMARDs in RA, the “JAK-pot” study. JAKi and TNFi with more rapid early improvement in CDIA, HAQ, and pain compared to ABA or IL-6 inhibitors…..although effects blunted after adjusting for patient and RA characteristics #ACR24 @RheumNow ABST#0501 https://t.co/8M4wX3LAbW

Links:

Jiha Lee JihaRheum ( View Tweet)
How does #cardiovascular risk vary with #ACPA & #biologics in #RA? ⬆️BMI assoc with ⬆️MACE risk in ACPA+ pts In ACPA- pts, BMI inversely assoc with MACE risk among pts on biologics Further evidence to consider ACPA, BMI & MACE as part of RA management Ab0870 #ACR24 @RheumNow https://t.co/UkkC146DWS

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Cross-sectional study finds metabolic dysregulation in RA-ILD is indicative of poor prognosis- FGF-21 assoc w. poor survival. Another link btwn CV risk factors, metabolic syndrome & RA? Should we be doing more to manage metabolic risk factors in RA-ILD? Ab0803 #ACR24 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

Not just the presence but higher levels of biomarkers predict RA-ILD progression. #ACR24 @RheumNow ABST#0804 https://t.co/5jhBjXDUeY

Links:

Jiha Lee JihaRheum ( View Tweet)
Medication-assisted weight loss has boomed in recent yrs. How does weight loss affect disease activity & PROs in RMDs? ≥5% weight loss, after taking a med, led to better disease activity & QoL Data may inform RCTs to explore effect of these meds in RMDs Ab0845 #ACR24 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

Don’t miss the “window of opportunity” for aggressive treatment in early RA! with active RA, risk of ILD 6x and RA-related lung disease 4x higher #ACR24 @RheumNow ABST#0802 https://t.co/yxlfInte6A

Links:

Jiha Lee JihaRheum ( View Tweet)
What's the assoc between RA disease activity & ILD? Results @MassGenBrigham show early active RA is assoc with ➡️6x incr risk of #ILD ➡️4x incr risk of RA-related lung disease Early DMARDs are vital to reduce articular & extra-articular manifestations! Ab0802 #ACR24 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

McDermott @jeffsparks et al. SAIL-RA prospective study. 172 early RA patients. RA lund disease in 16%, RA-ILD in 11%. Disease activity strongest predictor RA lung disease, HR 4.89, and RA-ILD, HR 6.17. @RheumNow #ACR24 Abstr#0802 #ACRbest https://t.co/ia0koG64mL https://t.co/U1KdgcUfOy

Links:

Richard Conway RichardPAConway ( View Tweet)

McDermott @jeffsparks et al. SAIL-RA prospective study. 172 early RA patients. RA lund disease in 16%, RA-ILD in 11%. Disease activity strongest predictor RA lung disease, HR 4.89, and RA-ILD, HR 6.17. @RheumNow #ACR24 Abstr#0802 #ACRbest https://t.co/ia0koG64mL https://t.co/U1KdgcUfOy

Links:

Richard Conway RichardPAConway ( View Tweet)
Ab#0427 #ACR24 HSS: menopause & systemic rheum disease severity 1/3 women report worse disease associated w menopause Reported more flares, menopausal symptoms Findings were similar between SLE and RA, but SLE patients were >2x more likely to discuss w their rheum @RheumNow

Eric Dein ericdeinmd ( View Tweet)

❔Can rheum drugs have beneficial effects on cognition? 💊Possible benefits with MTX and TNFis but certainly an active area of research and more studies needed #ACR24 @RheumNow https://t.co/lCnIRLwNjK

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Ab#474 #ACR24 Hsieh and @NamrataRheum Cancer Survival in RA Unable to do meta-analysis due to lack of data HR for lung cancer in RA 1.04 No clear evid of increased risk, but more data and studies needed Great research project by a high school student (!!) @RheumNow https://t.co/Sfrf2v2UO4

Links:

Eric Dein ericdeinmd ( View Tweet)
Ab#0458 #ACR24 10 year outcomes of 176 patients with seroneg RA 32 pts (18%) had change in dx - SpA (11), seropos RA (6), OA (5), crystal (3), CTD (3), Ifn-related/paraneopl/RS3PE, sarcoid (1) 40 (23%) had drug-free remission 30 (17%) started b/tsDMARD @RheumNow

Eric Dein ericdeinmd ( View Tweet)

👴🏼 Ageing & RMDs at #ACR24 🧠 14 factors associated with dementia ❗️Justin Levenson tells us that if we could address all of these, we could reduce dementia risk by 45%! @RheumNow https://t.co/SgC5KMohXy

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Interim analysis of a Phase 4 study of ARD (RA 25%, SLE 25%) patients shows recombinant herpes zoster vaccine(RZV) good safety profile, with no impact on disease activity (flare rates: 13.6% vs. 12.4%). Immunogenicity: 93% response in ARDs vs. 99% in controls. Rituximab & MMF… https://t.co/U3s48fLduX https://t.co/WTvD5shtXB

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.